Kyung Hee University has disclosed microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors acting as prostaglandin E2 (PGE2) production inhibitors reported to be useful for the treatment of asthma, atherosclerosis, diabetes, pain, osteoporosis, bursitis, infections and cancer.
Vidac Pharma Holdings plc has released promising results for VDA-1275 in mouse cancer and human cellular organoid models of solid tumors, with VDA-1275 showing efficacy as a monotherapy and synergistic effects in combination with sorafenib and cisplatin.
Biopsies from up to 14% of patients with non-small-cell lung cancer (NSCLC) showing resistance to epidermal growth factor receptor (EGFR) tyrosine kinase therapy ascertain histologic transformation (HT) to SCLC, which is estimated to kill around 250,000 patients globally, every year. In a study published in Science on Feb. 9, 2024, researchers from Weill Cornell Medicine have dissected that complex process using a genetically engineered mouse model of pulmonary HT.
Researchers from National Taiwan University combined the structural features of purine-type microtubule-disrupting compounds and histone deacetylase (HDAC) inhibitors, which led to the discovery of a novel series of dual-targeting compounds, with the purine-hydroxamate conjugate [I] selected as the lead candidate.
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. have announced a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
Doma Biopharmaceutical (Suzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies (E-6C4-M-2F11) targeting EGFR (HER1; erbB1) and hepatocyte growth factor receptors (HGFR; MET) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer and achondroplasia.
As gene therapies gain unprecedented traction into 2024, preclinical-stage South Korean biotech Genecraft Inc. said it raised ₩10 billion (US$7.48 million) in a series A financing to further R&D for its therapy against lung cancer.
